Beckley Waves (via NueCo Holdings PBC) Acquires Nue Life Health

Eli Lilly Acquires AtaiBeckley

July 17, 2026

Biotechnology

Eli Lilly agreed to acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, plus contingent value rights worth up to an additional $2.50 per share. The acquisition, valued at approximately $2.8 billion upfront, gives Lilly AtaiBeckley’s clinical-stage neuroplastogen pipeline, including programs for treatment-resistant depression; it was completed on September 11, 2026.

Quantum Surgical Acquires NeuWave Medical

February 27, 2026

Medical Devices

Quantum Surgical has acquired NeuWave Medical and combined both businesses under a newly created parent, Precision IO Group Inc., to expand a robotic-assisted tumor ablation platform. The deal is supported by investment from Ally Bridge Group and aims to integrate Quantum Surgical's Epione robotic system with NeuWave's microwave ablation technology to broaden access to minimally invasive interventional oncology care.

PhaseWell Research Acquires Bio Behavioral Health

January 21, 2026

Healthcare Services

PhaseWell Research, a national clinical research site company, announced that Bio Behavioral Health has joined its network to expand access to neuropsychiatric and CNS clinical trials. The deal strengthens PhaseWell's community-based research capabilities and broadens patient access to complex clinical studies across its growing national footprint.

Beckley Psytech Acquires Eleusis Therapeutics Limited

October 24, 2022

Biotechnology

Beckley Psytech Limited has acquired 100% of Eleusis Therapeutics Limited in an all-equity transaction, adding Eleusis' clinical-stage assets (including ELE-101) and its R&D team to Beckley's pipeline. Eleusis CEO Shlomi Raz will join Beckley as Chief Business Officer as the companies integrate to accelerate development of short-duration psychedelic therapies.

Blue Water Ventures International Acquires Psycheceutical, Inc.

January 20, 2022

Biotechnology

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

Neon Bloom, Inc. Acquires Bazelet Health Systems, Inc.

March 18, 2021

Biotechnology

Neon Bloom, Inc. (OTC: NBCO) has completed an all-stock acquisition of 100% of Bazelet Health Systems, Inc., issuing 120,000,000 Neon Bloom common shares. The deal brings Bazelet’s plant science, CRISPR-based genome engineering capabilities and accredited cannabis education business under Neon Bloom to accelerate research, commercialization and expansion in the legal cannabis/hemp and life‑sciences markets.